New Users  |  Log In Contact Us


Home



Untitled

Awards
Chemotherapy Course
Communiques
Discussion
Download Forms
Education
Find Other SIGs
Join A SIG
Membership Directory
Minutes
SIG Annual Report
SIG Leadership
SIG Newsletter
Health Policy
Peer Reviewed Journals
EBP Resources
Terms of Use
SIG Checklist
Focus Groups


Updated July 7 2014

Articles of Interest

 
Download zip

Files / Folders File Size Posted By Date Posted Actions
NTR FG Goals 4 12.pdf
ONS Nutrition Focus Group
61k seisenberg 4/19/12  
Syllabus Slides.8.2011 .FINAL.ppsx
2011 IOL Powerpoint presentation on Chemotherapy
2032k seisenberg 11/29/11  
Infusion Reactions (Vogel 2010).pdf
CJON OnLine Exclusive
230k seisenberg 4/13/10  
Trastuzumab-Induced Cardiotoxicity (5MI).pdf
Five Minute Inservice version of ONF article
173k seisenberg 12/9/09  
Prevent Extravasation Injury With the Use of Antidotes.pdf
From Vesicant Chemotherapy Extravasation Antidotes and Treatments by Lisa Schulmeister, RN, MN, APRN-BC,OCN®, FAAN. CJON August 2009.
166k seisenberg 9/1/09  



September 23, 2014




Chemotherapy & Biotherapy SIG


Welcome to the Chemotherapy and Biotherapy SIG Virtual Community page. You can view resources, download policies and order sets, join in our discussions and much more. We welcome your comments and feedback. Let us know how we can better support you in your practice.

NEW forms have been added to the Download section. If you haven't been there in a while, take a look around. As always, if you have any forms/orders/policies you'd like to share, please send me an email! Webmaster.



SIG Congress Recap

Follow THIS link to view the 2014 SIG Poster, presented at Congress.

Follow this link to the Congress SIG presentation by Kristine Abueg, RN, MSN, OCN®, CBCN



Vote on 'Does your facility provide compensation for administering chemotherapy?'

Does your facility provide compensation for administering chemotherapy?
Yes (monetary)
Yes (non-monetary)
No


Vote on 'Do you infuse Vincristine IVP or IVPB?'

Do you infuse Vincristine IVP or IVPB?
A. IV Push
B. IV Piggyback


Vote on 'Does your facility require sterile procedure for accessing implanted ports?'

Does your facility require sterile procedure for accessing implanted ports?
[Defined by using sterile gloves and a mask for the RN]
Yes
No


Evidence-Based Symptom Management Resources at Your Fingertips

From the team that has brought you the Putting Evidence Into Practice (PEP) resources since 2006 comes the first-ever pocket-sized book containing everything you need to immediately improve patient care.  Get the most current evidence-based information on 19 symptoms in this new, easy-to-carry guide.

Putting Evidence Into Practice: A Pocket Guide to Cancer Symptom Management

Edited by M. Irwin and L.A. Johnson

Use code PPEPC10 through November 1 and save 10% on your order of Putting Evidence Into Practice: A Pocket Guide to Cancer Symptom Management!

To order, visit www.ons.org/store or contact customer service at 866-257-4ONS.

Putting Evidence Into Practice: A Pocket Guide to Cancer Symptom Management updates the popular ONS PEP oncology symptom management resources into a portable pocket guide. Featuring the latest evidence on 19 symptom management topics, this book provides a quick-reference guide to help clinicians identify which interventions have demonstrated effectiveness against symptoms. The book is an essential tool for ensuring quality care of patients with cancer and was designed for easy carrying and referencing during direct patient care.

Each chapter outlines the nature, incidence, and impact of the symptom for patients with cancer; factors that create the highest risk; key aspects of assessment and identification of some assessment tools; intervention evidence; and suggestions for application in practice.

The following symptoms are covered.

•             Anorexia

•             Anxiety

•             Caregiver strain and burden

•             Chemotherapy-induced nausea and vomiting

•             Cognitive impairment

•             Constipation

•             Depression

•             Diarrhea (chemotherapy- and radiation-induced)

•             Dyspnea

•             Fatigue

•             Hot flashes

•             Lymphedema

•             Mucositis

•             Pain (acute, breakthrough, chronic, and refractory/intractable)

•             Peripheral neuropathy

•             Prevention of infection (general and transplant)

•             Radiodermatitis

•             Skin reactions

•             Sleep-wake disturbances

 

ISBN: 9781935864547 • Item INPU0650

ONS Member: $59 • Nonmember: $82.60

View ONS’s complete list of books at www.ons.org/store



Vote on ' 'Does your institution require some type of mandatory ANNUAL chemotherapy competency or review?''

'Does your institution require some type of mandatory ANNUAL chemotherapy competency or review?'
Yes
No


Names of Targeted Therapies Names of Targeted Therapies

The Names of Targeted Therapies Give Clues to How They Work

by Deborah Christensen RN, BSN, HNB-BC

 

I was reading through the program of my granddaughter's dance recital and noticed that there was not a single common name in the first three groups of young dancers. It was as if their parents purposefully decided to come up with the most unique names possible. There may have been some family significance in the names, but it was hard to tell without knowing the family. This is not the case with the family names of targeted cancer drugs. Each generic name gives information on the what, how, and where of each particular drug.

In contrast to traditional chemotherapeutic agents that affect rapidly dividing cells, targeted agents are more precise in the way they fight cancer. Presently, two main families of targeted therapies exist—monoclonal antibodies and small molecule inhibitors. The ending letters (stem) of the generic names are like surnames that tell what family the drug is from and how the drug works to kill cancer cells. Monoclonal antibodies end with the stem “-mab” and small molecule inhibitors end with the stem “-ib”. The “-mab” family of targeted therapies has three distinct methods for interfering with cancer cell growth.

 

  1. Attach to receptors on the outside of cells to prevent the receptors from interacting with signaling molecules (e.g., growth factor receptors and growth factor interaction)
  2. Deliver radioactive molecules or toxins to the inside of the cells through attachment to cellular receptors
  3. Activate the body’s natural immune response

 

The “-mab” family is used when receptor targets are overexpressed on the outside of cancer cells. Conversly, the “-ib” family targets processes within the cell and therefore must be small enough in molecular weight to enter the cell and interfere with proteins on both the inside and outside of the cell. Proteins that code for growth or inhibit growth are some of the targets of this small but powerful family of drugs.

The sub stem of the generic names of the “-mabs” identifies the source where the antibodies were generated or cloned. The three most common sources are:

 

  1. Chimeric human-mouse—drugs ending in “-ximab” (i.e., rituximab)
  2. Humanized mouse—drugs ending in “-zumab” (i.e., bevicizumab)
  3. Fully human—drugs ending in “-mumab” (i.e., ipilimumab)

 

Finally, both “-mabs” and “-ibs” contain an additional stem to describe the targeted therapies bullseye. For example, the “tu” in rituximab indicates the target is the tumor, the “ci” in bevicizumab designates the circulatory system, and the “li” in ipilimumab identifies the immune system target. Some of the intracellular targets for the “-ibs” include:

 

  1. Tyrosine kinase inhibition—sub stem “-tinib” (i.e., imatinib)
  2. Proteasome inhibition—“-zomib” (i.e., bortezomib)
  3. Clyclin-dependent kinase inhibition—“-ciclib” (i.e., seliciclib)

 

The prefix of the generic names and the drug market names are where researchers and pharmaceutical companies—like the parents of the young dancers—take creative liberty.

The development of targeted therapies is expected to accelerate as new targets are identified; as a result, oncology nurses will need to stay up to date on the new medications so they can educate their patients on the way these therapies work as well as the possible side effects of the medications. Unfortunately, many people may have the idea that there are few if any side effects associated with targeted therapy. Although side effects can be less than those of standard chemotherapy, targeted therapies also affect normal cells to some degree.

So how do nurses keep up on the new therapies? Recently, ONS merged two key special interest groups (SIGs) the Targeted and Biologic Therapies SIG and the Chemotherapy SIG. The new SIG is now called the Chemotherapy and Biotherapy SIG. Another resource I found especially helpful was an animated video titled Understanding Targeted Cancer Therapies presented by the National Institute of Health.  

Identifying the source, target, and mechanism of action by uncoding the generic names of targeted therapies is fun. It is a whole lot easier than trying to figure out how parents come up with clever names for their children.

 



CHE SIG Celebrates 25th Anniversary in 2014

The Chemotherapy & Biotherapy SIG will be celebrating their 25th Anniversary in 2014. The CHE SIG and Biotherapy SIG (separate at the beginning) were approved in August of 1989 with 42/CHE SIG charter members and 55/BIO SIG charter members. There have been many CHE/BIO SIG leaders who contributed to our history:
Biotherapy SIG                                                                                                      Chemotherapy SIG
Jacquelyn Beauregard-Dillman BA BS RN                                                                Sara Carter RN

Janet Appelbaum RN MS                                                                                        Pamela Kennedy RN

Eileen Sharp RN BSN                                                                                             Maryanne Fishman RN MS AOCN®

Nancy Moldawer RN MSN                                                                                       Mervianna Thompson RN BN MSN ANP

Janet DiJulio RN MSN                                                                                             Jeannie VanderKruik BA RN BSN OCN®

Danielle Gale ND MSN AOCNP®                                                                             Christina (Garda) White RN OCN®

Peggy Esper DNP(c) MSN ANP-BC AOCN®                                                             Kathy Wilkinson RN BSN OCN®

Paula Muehlbauer RN MSN AOCNS®                                                                      Jeanne Held-Warmkessel MSN RN AOCN® AOCNS-BC

Brenda Keith RN MN AOCNS®                                                                                Seth Eisenberg RN ASN OCN®

Kristine Abueg RN MSN OCN® CBCN®                                                                   Mildred Toth RN MS AOCN®

                                                                                                                             Myra Davis-Alston RN MSN/ED OCN® CRNI

                                                                                                                             Martha Polovich PhD RN AOCN®



2014 Chemotherapy/Biotherapy Course Changes

Learn more about the changes to the 2014 Chemotherapy/Biotherapy Course with these Frequently Asked Questions.

2014 SIG Leadership Workshop

 

Pre-Work:

Presentations:

Documents:






Television broadcast about hazardous drugs

Follow this link to view a televised investigative report about the hazards of handling chemotherapy--and why you need to take precautions.

http://video.kcts9.org/video/1540454085/




Related Links

Chemotherapy SIG Newsletter
ONS Board of Directors
SIG Communiques


Have a suggestion for this website?

Want additional content? Have an idea for a poll? Email your ideas to the Webmaster.



Powered by Readyportal Sitemap | Home

Copyright 2014 SIG. All rights reserved.